Abstract
Twenty-two premature infants with chronic lung disease (median gestational age 28 weeks) received polyribosylribitol phosphate-outer membrane protein conjugate Haemophilus vaccine at 2 and 4 months of chronologic age. The proportions with antibodies to polyribosylribitol phosphate at levels > 1 microgram/ml after doses 1 and 2 were 27% and 55%; geometric mean titers were 0.43 and 0.73 microgram/ml, significantly lower than values for term infants.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Age Factors
-
Antibody Formation
-
Bacterial Outer Membrane Proteins / administration & dosage
-
Bacterial Outer Membrane Proteins / immunology*
-
Chronic Disease
-
Diphtheria-Tetanus-Pertussis Vaccine / administration & dosage
-
Diphtheria-Tetanus-Pertussis Vaccine / immunology
-
Haemophilus Vaccines / administration & dosage
-
Haemophilus Vaccines / immunology*
-
Humans
-
Infant
-
Infant, Newborn
-
Infant, Premature
-
Infant, Premature, Diseases / immunology*
-
Lung Diseases / immunology*
-
Polysaccharides, Bacterial / administration & dosage
-
Polysaccharides, Bacterial / immunology*
-
Prospective Studies
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology*
Substances
-
Bacterial Outer Membrane Proteins
-
Diphtheria-Tetanus-Pertussis Vaccine
-
Haemophilus Vaccines
-
Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine
-
Polysaccharides, Bacterial
-
Vaccines, Synthetic